Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $28.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE